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Worldwide, cervical cancer is now the fourth most common female
malignancy in both incidence andmortality, followingbreast, colorectal,
and lung cancers, and results in approximately 527 600 new cases and
265 700 deaths annually [1]. It is the secondmost commonly diagnosed
cancer and thirdmost common cause of cancer death among females in
low-resource countries. More than 85% of new cases are diagnosed in
economically disadvantaged people. Nearly 90% of cervical cancer
deaths occur in low-resource regions of the world.1.1. Anatomy
The cervix is the lower aspect of the uterus. It is roughly cylindrical
in shape, projects through the superior-anterior vaginal wall, and
communicates with the vagina through the endocervical canal, which
terminates in the external os located at the top of the vagina. Cancer
of the cervix may originate from themucosa of the surface of the cervix
or from within the canal. Carcinoma of the uterine cervix grows locally
andmay extend in continuity to the uterus and paracervical tissues, and
pelvic organs.
Cervical cancer may spread to regional lymph nodes, and only later
metastasize hematogenously to distant structures. Studies on sentinel
lymph nodes show that the cervix is drained into the following ﬁrst
echelon nodal stations most commonly: external iliac (43%), obturator
(26%) and parametrial (21%), from where they drain to the common
iliac nodes. From the common iliac nodes, lymph drainage goes to the
para-aortic nodes. The most common sites of distant spread include
the para-aortic, mediastinal and supraclavicular nodes, the lungs, liver,
and skeleton.2. Staging
FIGO staging is based on clinical examination. The FIGO staging
guidelines were most recently updated in 2009 (Table 1) [2]. Stage 0
is no longer included in the FIGO 2009 staging.
A thorough pelvic examination is mandatory to provide information
for FIGO staging, and this rarely requires anesthesia. When there is
doubt as to which stage a particular cancer should be allocated, the ear-
lier stage is mandatory.http://dx.doi.org/10.1016/j.ijgo.2015.06.004
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).The following examinations are permitted for the determination of
FIGO staging, as indicated by presenting characteristics (see sections
below): palpation, inspection, colposcopy, endocervical curettage, hys-
teroscopy, cystoscopy, proctoscopy, intravenous pyelography, ultra-
sound of the renal tract, and X-ray examination of the lungs and
skeleton. Blood tests should include full blood count, and renal and
liver functions. Syphilis and HIV serology need to be considered, based
on discussion with the patient about risk factors.2.1. Initial assessment of microinvasive disease
The diagnosis of both Stage IA1 and IA2 should be based on micro-
scopic examination of removed tissue, preferably a cone biopsy, which
must include the entire lesion. The depth of invasion should not be
greater than 5mm taken from the base of the epithelium, either surface
or glandular, from which it originates. The second dimension, the hori-
zontal spread, must not exceed 7 mm. Vascular space involvement,
either venous or lymphatic, should not alter the staging, but should be
speciﬁcally recorded because it may affect treatment decisions. Macro-
scopically obvious lesions, and those with larger dimensions, should
be staged as IB. It is impossible to clinically determine if a cancer of
the cervix has extended to the corpus. Extension to the corpus should
therefore be disregarded for staging purposes.
The diagnosis of Stage IA1 or IA2 disease can only be made on the
basis of a cone biopsy with negative margins, or on a trachelectomy or
hysterectomy specimen. If the margins of the cone biopsy are positive
for cervical intraepithelial neoplasia (CIN) III or invasive cancer, a sec-
ond cone biopsy should be performed or the patient treated as for
Stage IB1 disease [3].2.2. Initial evaluation of grossly invasive disease
Visible lesions require a biopsy to conﬁrm a diagnosis of cervical
carcinoma. A patient with a growth apparently ﬁxed to the pelvic wall
by a short and indurated, but not nodular, parametrium should be
allotted to Stage IIB. Stage III should be deﬁned for cases where the
parametrium is nodular to the pelvic wall or if the growth itself extends
to the pelvic wall. The presence of hydronephrosis or non-functioning
kidney(s) resulting from obstruction of the ureter(s) by cancer also per-
mits a case to be allotted to Stage III.Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Table 1
Cancer of the cervix uteri.
Stage Description
I The carcinoma is strictly conﬁned to the cervix (extension to the uterine corpus should be disregarded).
IA Invasive cancer identiﬁed only microscopically. (All gross lesions even with superﬁcial invasion are Stage IB cancers.) Invasion is limited to
measured stromal invasion with a maximum depth of 5 mm and no wider than 7 mm.
IA1 Measured invasion of stroma ≤ 3 mm in depth and ≤ 7 mm width.
IA2 Measured invasion of stroma N 3 mm and b 5 mm in depth and ≤ 7 mm width.
IB Clinical lesions conﬁned to the cervix, or preclinical lesions greater than stage IA.
IB1 Clinical lesions no greater than 4 cm in size.
IB2 Clinical lesions N 4 cm in size.
II The carcinoma extends beyond the uterus, but has not extended onto the pelvic wall or to the lower third of vagina.
IIA Involvement of up to the upper 2/3 of the vagina. No obvious parametrial involvement.
IIA1 Clinically visible lesion ≤ 4 cm
IIA2 Clinically visible lesion N 4 cm
IIB Obvious parametrial involvement but not onto the pelvic sidewall.
III The carcinoma has extended onto the pelvic sidewall. On rectal examination, there is no cancer free space between the tumor and pelvic sidewall.
The tumor involves the lower third of the vagina. All cases of hydronephrosis or non-functioning kidney should be included unless they are known
to be due to other causes.
IIIA Involvement of the lower vagina but no extension onto pelvic sidewall.
IIIB Extension onto the pelvic sidewall, or hydronephrosis/non-functioning kidney.
IV The carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder and/or rectum.
IVA Spread to adjacent pelvic organs.
IVB Spread to distant organs.
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hydronephrosis (with renal ultrasound, intravenous pyelography, CT,
or MRI) are mandatory. The bladder and rectum are evaluated by cys-
toscopy and sigmoidoscopy only if the patient is clinically symptomatic.
Cystoscopy is also recommended in cases of endocervical growth with
a barrel-shaped surface and in cases where the growth has extended
to the anterior vaginal wall. Suspected bladder or rectal involvement
should be conﬁrmed by biopsy and histologic evidence. The presence
of bullous edema, as such, should not permit a case to be allotted to
Stage IV.
Imaging evaluationmay be of additional beneﬁt to clinical examina-
tion in practice areas where resources allow. Imaging may allow for
identiﬁcation of additional prognostic factors and help direct selection
of therapy. MRI provides the best radiologic assessment of primary
tumors greater than 10 mm, but is not mandatory [4–8]. Level of
Evidence B
CT and/or MRI and/or positron emission tomography (PET) may
provide information on nodal status or systemic spread, but are not
mandatory. Compared with CT and MRI, PET-CT is a more accurate im-
aging method for detecting nodal metastasis that are greater than
10 mm [5,9–12]. Isolated and unexpected areas of PET enhancement
should be further investigated with tissue diagnosis, if possible, to con-
ﬁrm or exclude the presence of distant metastatic disease [11,13,14].
Level of Evidence B
Compared with radiologic evaluation, surgical node dissection is
more accurate for assessment of para-aortic nodal disease [15,16]. In pa-
tients with advanced disease, laparoscopic staging of para-aortic lymph
nodes may be considered to allow treatment according to extent of
disease [17]. No impact on survival has been demonstrated; however,
surgical exclusion of para-aortic lymph node involvement portends a
better prognosis than radiographic exclusion alone [18]. Level of
Evidence B
In a review of 22 articles that evaluated the safety and impact of pre-
treatment surgical para-aortic lymph node staging (PALNS), para-aortic
lymph node metastases were found in 18% (range, 8%−42%) of
patients with cervical cancer Stage IB-IVA [19]. The mean complication
rate of PALNSwas 9% (range, 4%−24%), themost common complication
being lymphocysts. PET-CT appears to be the most accurate imaging
method, with false-negative results in 4%−15% of cases. Positive para-
aortic nodes have been identiﬁed in up to 35% of Stage IIB and 20% of
Stage III tumors [19]. Knowing the status of para-aortic nodes may pro-
vide prognostic information as well as guide the extent of adjuvant or
primary radiation. It is, however, controversial and is not recommendedas a routine practice, particularly in resource-restricted environments
and in women with advanced disease associated with constitutional
symptoms.
2.3. Pathologic staging
In cases treated by surgical procedures, the pathologist’s ﬁndings in
the removed tissues can be the basis for accurate statements on the ex-
tent of disease. Theﬁndings should not be allowed to change the clinical
staging, but should be recorded in the manner described for the patho-
logic staging of disease. The TNM nomenclature is appropriate for this
purpose [20]. Unlike FIGO staging criteria, TNM staging accounts for
node positivity; however, the FIGO and TNM classiﬁcations are other-
wise virtually identical in describing the anatomical extent of disease.
Clinical staging is essential to select and evaluate therapy, while the
pathological stage provides the most precise data from which to esti-
mate prognosis and calculate end results.
Infrequently, hysterectomymay be carried out in the presence of un-
suspected invasive cervical carcinoma. Such cases cannot be clinically
staged or included in therapeutic statistics, but it is desirable that they
be reported separately. If considered appropriate, someof these patients
may be offered repeat laparotomywith full parametrectomy and pelvic
lymphadenectomy to allow potentially curative surgery and/or deter-
mine the need for adjuvant chemoradiation [21].
Staging is determined at the time of the primary diagnosis and can-
not be altered, even at recurrence. Only if the rules for clinical staging
are strictly observed is it possible to compare results among clinics
and by differing modes of therapy.
2.4. Histopathology
All tumors must be microscopically veriﬁed. Cases should be clas-
siﬁed as carcinomas of the cervix if the primary growth is in the
cervix. All histologic types must be included. The histopathologic
types are:
• Squamous cell carcinoma (keratinizing; non-keratinizing; verrucous).
• Endometrioid adenocarcinoma.
• Clear cell adenocarcinoma.
• Adenosquamous carcinoma.
• Adenoid cystic carcinoma.
• Small cell carcinoma.
• Undifferentiated carcinoma.
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formodifying the stage groupings. Histopathologic grades are as follows:
• GX: Grade cannot be assessed.
• G1: Well differentiated.
• G2: Moderately differentiated.
• G3: Poorly or undifferentiated.
When surgery is the primary treatment, the histologic ﬁndings per-
mit the case to have pathologic staging, as described above. In this situ-
ation, the TNM nomenclature may be used.
3. Cervical cancer screening
Primary prevention of cervical cancer through HPV vaccination of
girls, and secondary prevention through the detection of cervical cancer
precursors by various screening methods and their appropriate
treatment, are both known to be effective preventive measures.
Details on cervical cancer screening can be accessed via the FIGO
website (www.ﬁgo.org).
4. Management of cervical cancer
4.1. Microinvasion
4.1.1. Stage IA1
Conization is the treatment of choice for this stage. If the patient has
completed childbearing, hysterectomy (abdominal, vaginal, or laparo-
scopic) may be considered [22].
Follow-up with Pap smears every 3 months for 2 years, and
then every 6 months for a further 3 years should be performed. If
follow-up is normal at 5 years, the screening schedule may be complet-
ed according to the recommendations in each country [23,24]. Level of
Evidence C
4.1.2. Stage IA2
Since lymph nodesmay be involved in this stage, lymphadenectomy
is necessary [25,26]. The recommended treatment is type 2 radical
hysterectomy (ligation of the uterine artery where it crosses the ureter,
although a vaginal cuff is not necessary) with pelvic lymphadenectomy.
If fertility is desired, options are: (1) cervical conization with extra-
peritoneal or laparoscopic pelvic lymphadenectomy; or (2) radical
abdominal, vaginal, or endoscopic trachelectomy with pelvic lymphad-
enectomy performed according to the surgical approach [27,28].
4.1.3. Post-treatment follow-up after microinvasive carcinoma
Follow-up with Pap smears every 3 months for 2 years, and
then every 6 months for a further 3 years should be performed. If
follow-up is normal at 5 years, the screening schedule may be complet-
ed according to the recommendations in each country [23,24]. Level of
Evidence C
4.2. Grossly invasive cervical carcinoma (FIGO Stage IB–IVA)
Concurrent platinum-based chemoradiation is the most indicated
treatment for this stage although neoadjuvant chemotherapy may
play a role in selected settings [29]. The treatment approach should be
decided based on the availability of resources, and tumor- and
patient-related factors.
4.2.1. Surgical management
Surgical treatmentmay be indicated in Stage IB1–IIA1 disease: mod-
iﬁed radical or radical (abdominal or endoscopic) hysterectomy with
pelvic lymphadenectomy [30–32]. Level of Evidence B
Primary pelvic exenterationmay be considered for Stage IVA disease
without extension to the pelvic sidewall or extra-pelvic disease [33–46].
Level of Evidence C4.2.1.1. Sentinel lymph node assessment
Identiﬁcation of sentinel lymph nodes can be performed with dual
labeling using blue dye and radiocolloid [47–49]. These procedures
may be considered in early stage cervical cancer, Stage IA and IB1
[50–52].
If lymphovascular space invasion is present, pelvic lymphadenecto-
my needs to be considered. Level of Evidence C
Sentinel lymph node assessment of pelvic lymph nodes should not
be utilized in advanced disease [53].
4.2.1.2. Trend to lesser surgery for small tumors
Stages IA2–IB1with tumor size of less than 2 cm, cervical stromal in-
vasion of less than 50%, and node negative onMR/CT imaging have been
considered as low risk.
Simple hysterectomy or trachelectomy, with either pelvic lymphad-
enectomy or sentinel lymph node assessment, have been considered
as adequate surgical treatment for low-risk cases [54,55]. Level of
Evidence D
4.2.1.3. Adjuvant radiation/chemotherapy
The risk of recurrence after radical surgery is increased in the pres-
ence of positive nodes, positive parametria, or positive surgicalmargins.
Adjuvant concurrent chemoradiation (cisplatin with or without 5-
ﬂuorouracil) improves overall survival, progression-free survival, and
both local and distant recurrences compared with pelvic irradiation
alone in such patients [42]. Level of Evidence B
Risk of pelvic recurrence is also increased in those with uninvolved
nodes but with primary associated risk factors: tumor size greater
than 4 cm, capillary-like space (CLS) involvement, and outer one-third
invasion of the cervical stroma [43,44]. Adjuvant whole pelvic chemo-
irradiation reduces the local failure rate and improves progression-
free survival compared with patients treated with surgery alone [43].
Level of Evidence B
Adjuvant radiation therapy with and without chemotherapy
may be particularly beneﬁcial for patients with adenocarcinoma or
adenosquamous histology, given the relatively higher rates of distant
failure [42,43]. Level of Evidence C
Patients with positive common iliac or para-aortic nodes may be
treated by extended ﬁeld radiation [56,57], with or without chemother-
apy. Level of Evidence C
Intensity modulated radiation therapy has been explored in the
postoperative setting. A prospective multi-institutional study has
shown acceptable toxicities with this approach and a randomized trial
(TIME-C) is underway comparing intensity-modulated radiation thera-
py (IMRT) with standard ﬁeld-based radiation therapy in postoperative
cervical and endometrial cancer [58,59]. Although there is currently
insufﬁcient evidence at the present time to recommend IMRT as a stan-
dard of care, many centers have shifted to using this technique in post-
operative cervical and endometrial cancer treatment.
4.2.2. Neoadjuvant chemotherapy and surgery
The theoretical rationale for the use of neoadjuvant chemotherapy
(NACT) includes the induction of tumor shrinkage to facilitate radical
excision, and a possible improvement in outcomes over surgery alone.
There is also a possibility of NACT sterilizing nodes and parametria,
thereby reducing risk factors for adjuvant therapy after surgery; howev-
er, the efﬁcacy of neoadjuvant therapy in this situation is not known.
A meta-analysis of randomized trials of neoadjuvant platinum-
based chemotherapy prior to deﬁnitive surgery shows that patients
treated with NACT have better survival outcomes than those treated
with primary radiation alone, given at a relatively lowdose [60]. No ran-
domized data compare the results of NACT followed by surgery with
concurrent chemoradiation. The European Organization for Research
and Treatment of Cancer is currently conducting a Phase 3 study com-
paring NACT and surgery with deﬁnitive chemoradiation in patients
with FIGO Stages IB2, IIA2, or IIB cervical cancers.
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but its role is uncertain as a review of available literature suggests no
beneﬁt of NACT-surgery over upfront surgery plus adjuvant therapy
[61]. Optimal pathologic response, deﬁned as persistent residual disease
with less than 3 mm of stromal invasion in the surgical specimen, is
the strongest predictor of freedom from local recurrence for patients
treated with NACT and surgery [62]. A chemotherapy regimen of
paclitaxel, ifosfamide, and cisplatin has higher response rates than
ifosfamide and cisplatin for Stage IB2, although not for Stage IIB [63]. A
statistically signiﬁcant effect on overall survivalwas not found, although
this study was insufﬁciently powered for overall survival outcomes
[63]. Surgery after NACT should consist of radical hysterectomy and
pelvic lymphadenectomy.
Many patients randomized to NACT-surgery either were unable
to proceed with radical surgery after chemotherapy (40%) or required
additional adjuvant therapy after surgery (26%) [64]. NACT surgery
should be carefully considered in patients with larger tumors or adeno-
carcinomahistology owing to lower response rates. Stage IIB and higher
stages should be preferentially managed with deﬁnitive chemoradia-
tion therapy.
NACT obscures the pathologic ﬁndings at the time of surgery,
complicating evaluation of indications for adjuvant radiotherapy with
or without adjuvant chemotherapy. Indications for adjuvant therapy
after primary surgery [42,43] are often applied in the setting of NACT
surgery. Level of Evidence C
4.2.3. Primary radiation management
Chemoradiotherapy is the standard of care for patients with IB2,
IIA2, IIB, IIIA, IIIB, and IVA disease. Standard concurrent chemoradiation
therapy includes external radiation and intracavitary brachytherapy
[65,66]. Level of Evidence A
4.2.3.1. Radiation
Standard radiation treatment of cervical carcinoma is external pelvic
irradiation plus brachytherapy. Suggested doses of external beam radi-
ation are 45–50 Gy in 180–200 cGy per fraction. Standard radiation
planning techniques are outlined in Table 2. A full description of radia-
tion used in cervical cancer treatment is included in the radiation ther-
apy chapter included in the FIGO Cancer Report 2015 (this Supplement)
[67].
4.2.3.2. Total treatment time
Timely completion of radiotherapy is essential for optimal outcomes.
In retrospective trial data, patients with radiotherapy treatment times
of greater than 9–10 weeks had signiﬁcantly higher rates of pelvic fail-
ure, compared with women completing treatment in less than 6–7Table 2




Target volumes • Tumor plus uterus, parametrial tissue, and ut
• Pelvic lymph nodes (internal iliac, external il
• Margin for microscopic spread of disease
Field borders Tumor determined by palpation and CT scan (
A-P ﬁelds
Lateral: 2 cm lateral to the bony margin of the
Superior: L4/L5 or L5/S1 vertebral interspace
Inferior: 2 cm below the obturator foramen (o
Lateral ﬁelds
Anterior: anterior to symphysis pubis, 2 cm an
Posterior: posterior to sacrum to include poten
In patients with positive common iliac or para
Energy Irradiation should be given by an appropriate
18 MV generally provides a homogeneous dos
satisfactory pelvic radiation therapy can be achweeks [68,69]. It is recommended that all external beam radiotherapy
and brachytherapy be completed within 56 days.
4.2.3.3. Addition of chemotherapy to radiation
Concurrent chemoradiation confers a signiﬁcant overall survival
beneﬁt compared with the same radiation alone, with a meta-analysis
of 13 trials showing a ﬁve-year survival advantage of 6% (Hazard
Ratio: 0.81) [29]. Concurrent chemoradiotherapy also reduced local
and distant recurrence, and improved disease-free survival. Level of Ev-
idence A
A once-weekly infusion of cisplatin (40 mg/m2 weekly with appro-
priate hydration) for 5–6 cycles, is a commonly used concurrent chemo-
therapy regimen, and is equally effective and less toxic than combined
cisplatin and 5-ﬂuorouracil in a 21-day schedule during external
beam therapy [65,70]. For patients who are unable to receive platinum
chemotherapy, 5–ﬂuorouracil-based regimens are an acceptable alter-
native [29,71]. Data on the toxicity associated with concurrent chemo-
therapy and extended ﬁeld irradiation are limited [56,57].
Although randomized studies of chemoradiotherapy included pa-
tients with Stage IB2 and above, given the magnitude of the survival
beneﬁt, concurrent chemotherapy with a platinum-based regimen is
often recommended for any patient considered suitable for radical ra-
diotherapy, if the patient is ﬁt enough.
Additional adjuvant chemotherapy after concurrent chemoradio-
therapy is being explored in an international randomized controlled
trial (OUTBACK Trial) [72]. A single randomized study suggests possible
beneﬁt in progression-free and overall survival with additional chemo-
therapy, but with more severe toxicity [73]. At present there is insufﬁ-
cient evidence to recommend additional adjuvant chemotherapy as a
standard of care.
4.2.3.4. Resource-limited practices
Where available, brachytherapy constitutes an essential component
of radical radiotherapy or chemoradiotherapy. However, bulky tumors
may be curable with external beam radiation alone if brachytherapy
and/or chemotherapeutic agents are not readily available. Recognized
prognostic factors for probability of cure include lower stage, squamous
cell histology, and good performance status.
In situationswhere brachytherapy is not available, an external beam
boost is a reasonable option to achieve local control. A total radiation
dose of 54–70 Gy can provide local control rates of 52%, with a median
time to recurrence of 2.3 years [74].
4.2.3.5. Post-treatment follow-up
A systematic review of 17 retrospective trials for follow-up of
women after treatment for cervical cancer found the median time to
recurrence after treatment ranged from 7–36 months after primaryerosacral ligaments
iac, obturator, and presacral) and lower common iliac lymph nodes
if available) plus 2 cm margin
pelvis
r 2 cm below lower extent of clinical tumor)
terior to tumor
tial microscopic disease along the uterosacral ligament
-aortic nodes, extended ﬁeld radiation should be considered [56,57]
energy causing a uniform dose distribution (−5% to + 7%) within the target volume
e distribution in the target volume with 4-ﬁeld techniques. In resource-limited areas,
ieved with lower energy linacs or cobalt units
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been established and clinical practice is variable. Common recommen-
dations include educating patients about potential symptoms, history
taking, and clinical examination at routine follow-up intervals to detect
treatment complications and psychosexual morbidity, as well as to as-
sess for recurrent disease. Level of Evidence D
Commonly used tests include chest X-ray, ultrasound, CT scans, and
intravenous pyelography.
As isolated central recurrences are potentially curable, closer clinical
follow-up in the 2–3 years after treatment may be important. Routine
imaging is not indicated. Special circumstances, such as involved high
pelvic lymph nodes, may justify interval imaging of the abdomen to
assess for potentially curable progression of disease. In the systematic
review, asymptomatic recurrent disease was detected using physical
exam (29%−71%), chest X-ray (20%−47%), CT (0%−34%), and vaginal
vault cytology (0%−17%) [75]. Frequent vaginal vault cytology does
not signiﬁcantly improve the detection of early disease recurrence.
Patients should return to annual population-based screening after
5 years of disease-free survival [75].
4.3. Stage IVB/distant metastases
4.3.1. Systemic therapy
Presentation with distant metastatic disease is rare, reported in
about 2% of cases [76]. There has been no randomized comparison of
chemotherapy to best supportive care for Stage IVB cervical carcinoma.
Few studies have evaluated the impact of systemic therapy on palliative
and quality-of-life endpoints. There is some evidence that concurrent
chemoradiationmay have better response than systemic chemotherapy
[77]. Overall and disease-free survivals of 69% and 57% respectively have
been reported in patients with positive para-aortic and supraclavicular
lymph nodes [78]. Level of evidence D
A management plan should consider that the median duration of
survival with distant metastatic disease is approximately 7 months.
Despite limited response rates, cisplatin has been the standard
chemotherapy used in the setting of distant metastatic disease [79,80].
Given low response rates to cisplatin alone after concurrent chemoradi-
ation, recent evidence supports the use of platinum doublets over
cisplatin alone, although with very modest beneﬁts in response rates.
Cisplatin may be combined with taxanes, topotecan, 5-ﬂuorouracil,
gemcitabine, or vinorelbine [80]. Carboplatin-paclitaxel combination
has also been successful in these cases. In a recent study, the addi-
tion of bevacizumab in a dose of 15 mg per kg body weight to chemo-
therapy with a combination of either cisplatin-paclitaxel or topotecan-
paclitaxel was evaluated [81]. Bevacizumab increased the overall
survival (17.0 months vs 13.3 months; hazard ratio for death, 0.71;
98% CI, 0.54−0.95; P= 0.004 in a one-sided test) and higher response
rates (48% vs 36%, P = 0.008). Bevacizumab, as compared with che-
motherapy alone, was associated with an increased incidence of hyper-
tension of grade 2 or higher (25% vs 2%), thromboembolic events of
grade 3 or higher (8% vs 1%), and gastrointestinal ﬁstulas of grade 3 or
higher (3% vs 0%).Table 3
Eastern Cooperative Oncology Group (ECOG) performance status.
Grade ECOG
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to
carry out work of a light or sedentary nature, e.g. light house work,
ofﬁce work
2 Ambulatory and capable of all self-care but unable to carry out any work
activities. Up and about more than 50% of waking hours
3 Capable of only limited self-care, conﬁned to bed or chair more than 50%
of waking hours
4 Completely disabled. Cannot carry on any self-care. Totally conﬁned to bed
or chair
5 DeadPalliative systemic therapy may be considered for patients with
an ECOG (Eastern Cooperative Oncology Group) performance status
of 0–2 (Table 3). Discussion of participation in clinical trials should
be considered, particularly for patients who have relapsed within
12 months [82].
4.3.2. Palliative radiation for localized symptoms
Local treatment with radiation therapy is indicated to sites of symp-
tomatic involvement in patients with metastatic disease. Alleviation of
symptoms with palliative radiation can often be achieved for pain aris-
ing from enlarged para-aortic or supraclavicular nodes, skeletal metas-
tases [83], and symptoms associated with cerebral metastases. In view
of the short life expectancy of patients with metastatic cervical cancer,
palliative radiotherapy should be given via larger fractions over shorter
periods of time than conventional radical courses of treatment. There
are nodata to endorse speciﬁc dose/fractionation schemes for soft tissue
metastases; commonly used schedules include large single fractions,
20 Gy in ﬁve fractions, and 30 Gy in 10 fractions.
4.3.3. Comprehensive palliative care
Patients with incurable cervical cancer may develop a range of
challenging symptoms and should be managed on an individual basis.
Common problems associated with advanced cervical cancer can
include: pain, ureteric obstruction causing renal failure, hemorrhage,
malodorous discharge, lymphedema, and ﬁstulas. Patients may beneﬁt
from a wide range of clinical services to manage these symptoms, as
well as psychosocial care and support for patients and their families. Ac-
cess to oralmorphine is improvingwithin low-resource countries and is
an important aspect of palliative care.
4.4. Recurrent disease
Recurrences may be pelvic, para-aortic, distant, or a combination.
The risk of both pelvic and distant failure increases with the bulk of
disease [84,85]. The majority of recurrences occur within 3 years of
diagnosis, and the prognosis is poor, withmost patients dying as a result
of uncontrolled disease [86]. Treatment decisions should be based on
the performance status of the patient, the site of recurrence and/or me-
tastases, the extent of metastatic disease, and prior treatment [87].
For patients with extensive local disease or distant metastatic
disease, the intent of therapy is palliative, and best supportive care is
generally the recommended management. For patients with good per-
formance status and limited metastatic disease, a trial of platinum
doublet systemic therapy may be justiﬁed, understanding the limited
beneﬁts with respect to response rate and progression-free survival
[79,81]. Local recurrence that is not salvageable with surgery or radio-
therapy has a very poor response to systemic chemotherapy.
4.4.1. Local recurrence
Some patients with locally recurrent disease after deﬁnitive therapy
(surgery or radiotherapy) are potentially curable. Favorable prognostic
factors include an isolated central pelvic recurrence with no sidewall
disease, a long disease-free interval, and size of the recurrence less
than 3 cm in diameter [36,88].
Relapse in the pelvis following primary surgery may be treated by
either radical chemoradiation or pelvic exenteration. Radical irradiation
with or without concurrent chemotherapy) may result in ﬁve-year
disease-free survival rates of 45%–74% with isolated pelvic failure after
primary surgery [89,90]. The extent of recurrent disease and involve-
ment of pelvic lymph nodes are prognostic factors for survival [91].
Level of Evidence C
The radiation dose and volume should be tailored to the extent of re-
current disease; 45–50 Gy in 180 cGy fractions should be delivered to
areas likely to be involved with microscopic disease, and a boost dose
of up to 64–66 Gy to the gross tumor volume using ﬁeld reductions.
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Pelvic exenteration may be a feasible treatment option in selected
patientswhohave recurrence after radiation. Suitable candidates for ex-
enteration after previous surgery or pelvic radiation are patients with-
out evidence of intra-peritoneal or extra pelvic spread, and who have
a tumor-free space along the pelvic sidewall [33–37]. Level of
Evidence C
Owing to the morbidity of exenteration, its use is conﬁned to those
with curative potential, and requires careful patient selection regarding
the associated physical and psychological demands. Conﬁrmation of
recurrence with a pathologic specimen obtained by biopsy is essential
prior to proceeding with exenteration. A PET/CT is the most sensitive
non-invasive test to determine any sites of distant disease, and if possi-
ble, should be performed prior to exenteration [13,93–100]. Patient
assessment and counseling regarding the implications and ability to
manage stoma and ostomy sites must be addressed prior to surgery
[101]. Careful selection of patients may yield a ﬁve-year survival with
pelvic exenteration in the order of 30%–60% [33,34,36], and an operative
mortality of less than 10% [102].
4.4.2. Para-aortic nodal recurrence
After the pelvis, para-aortic lymph nodes are the nextmost common
site of recurrent disease. Possible long-term survival with radical-intent
radiotherapy or chemoradiotherapy can be achieved in approximately
30% of patients with isolated para-aortic nodal recurrence [103]. Pa-
tients with asymptomatic, low volume recurrences that occur greater
than 24 months from initial treatment have better outcomes [103].
Level of Evidence C
5. Special circumstances
5.1. Incidental cervical cancer
Invasive cervical cancer may be found during the pathological eval-
uation of the specimen of a simple hysterectomy for an apparently be-
nign condition. Overall survival is lower in cases of tumor cut-through
leaving residual disease [104]. When this circumstance happens, a
PET/CT scan if available, or a pelvic and abdominal CT or MRI scan and
chest imaging should be performed, to assess the extent of disease.
The treatment proposal should be tailored based on the histologic
and the radiologicﬁndings. Pelvic radiation (with orwithout concurrent
chemotherapy) and vaginal brachytherapy should be considered
[104–106]. Level of Evidence C
5.2. Cervical cancer during pregnancy
A multidisciplinary decision-making team with the involvement of
an obstetrician, neonatologist, psychologist, and spiritual advisor is rec-
ommended tomake a tailored individual therapeutic proposal. All plans
should be discussed with the patient (and preferably her partner), and
her wishes must be respected.
In general, the management of cervical cancer in pregnant
women follows the same principles as in non-pregnant women.
Cases before 16–20 weeks are treated without delay with either sur-
gery or chemoradiation.
From the second trimester onward, surgery and chemotherapy can
be used in selected cases while preserving the pregnancy [107]. Level
of Evidence C
If the diagnosis is made after 20 weeks, treatment delay appears to
be an option for Stages IA2 and IB1, with no apparent impairment of
prognosis compared with non-pregnant controls [108–110]. Treatment
consisting of classical cesarean delivery and radical hysterectomy is
often undertakenwhen a balance is reached between competingmater-
nal and fetal health risks, usually not later than 34 weeks of pregnancy.
Level of Evidence CFormore advanced disease, it is not knownwhether treatment delay
will affect survival. If a treatment delay is planned inwomenwith local-
ly advanced disease, neoadjuvant chemotherapy may be considered in
an attempt to prevent disease progression [111,112].
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